Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | beta-ketoacyl synthase, N-terminal domain-containing protein | 0.0016 | 0.1965 | 0.241 |
Onchocerca volvulus | 0.0043 | 0.9002 | 0.9555 | |
Echinococcus multilocularis | Ataxin 2, N terminal,domain containing protein | 0.0012 | 0.0965 | 1 |
Mycobacterium ulcerans | Type I modular polyketide synthase | 0.0025 | 0.4229 | 0.4065 |
Mycobacterium tuberculosis | Phenyloxazoline synthase MbtB (phenyloxazoline synthetase) | 0.0023 | 0.3806 | 0.5131 |
Loa Loa (eye worm) | hypothetical protein | 0.0014 | 0.1395 | 0.1211 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks7 | 0.0026 | 0.463 | 0.6242 |
Toxoplasma gondii | type I fatty acid synthase, putative | 0.0026 | 0.463 | 0.9359 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks15 | 0.001 | 0.0391 | 0.0527 |
Brugia malayi | Beta-ketoacyl synthase, N-terminal domain containing protein | 0.0025 | 0.4229 | 0.3988 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0027 | 0.4875 | 0.5 |
Brugia malayi | AMP-binding enzyme family protein | 0.0023 | 0.3806 | 0.3547 |
Mycobacterium leprae | Polyketide synthase Pks13 | 0.0037 | 0.7417 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0027 | 0.4875 | 0.5 |
Mycobacterium ulcerans | phenolpthiocerol synthesis type-I polyketide synthase PpsB | 0.002 | 0.297 | 0.172 |
Mycobacterium leprae | PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSC | 0.0026 | 0.463 | 0.481 |
Loa Loa (eye worm) | hypothetical protein | 0.0042 | 0.8611 | 1 |
Mycobacterium ulcerans | phenolpthiocerol synthesis type-I polyketide synthase PpsC | 0.0026 | 0.463 | 0.481 |
Mycobacterium tuberculosis | Polyketide synthase Pks2 | 0.0024 | 0.4032 | 0.5436 |
Loa Loa (eye worm) | fatty acid synthase | 0.0024 | 0.4143 | 0.4558 |
Loa Loa (eye worm) | AMP-binding enzyme family protein | 0.0023 | 0.3806 | 0.4147 |
Mycobacterium ulcerans | polyketide synthase | 0.0025 | 0.4229 | 0.4065 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks5 | 0.0024 | 0.4032 | 0.5436 |
Mycobacterium tuberculosis | Probable membrane bound polyketide synthase Pks6 | 0.0037 | 0.7417 | 1 |
Mycobacterium tuberculosis | Phenolpthiocerol synthesis type-I polyketide synthase PpsC | 0.0025 | 0.4229 | 0.5702 |
Mycobacterium ulcerans | polyketide synthase Pks13 | 0.0037 | 0.7417 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0027 | 0.4875 | 0.545 |
Brugia malayi | hypothetical protein | 0.0018 | 0.2362 | 0.2043 |
Brugia malayi | hypothetical protein | 0.0027 | 0.4875 | 0.4661 |
Leishmania major | hypothetical protein, conserved | 0.0027 | 0.4875 | 0.5 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks1 | 0.0018 | 0.2414 | 0.3255 |
Mycobacterium ulcerans | Type I modular polyketide synthase | 0.0025 | 0.4229 | 0.4065 |
Mycobacterium leprae | Probable multifunctional mycocerosic acid synthase membrane associated enzyme Mas | 0.0026 | 0.463 | 0.481 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0027 | 0.4875 | 0.5 |
Mycobacterium ulcerans | phenolpthiocerol synthesis type-I polyketide synthase PpsA | 0.002 | 0.297 | 0.172 |
Echinococcus granulosus | Ataxin 2 N terminaldomain containing protein | 0.0012 | 0.0965 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0027 | 0.4875 | 0.5 |
Mycobacterium tuberculosis | Polyketide synthase Pks12 | 0.0026 | 0.463 | 0.6242 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0027 | 0.4875 | 1 |
Mycobacterium ulcerans | phenolpthiocerol synthesis type-I polyketide synthase PpsD | 0.0025 | 0.4229 | 0.4065 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks8 | 0.002 | 0.3055 | 0.4119 |
Mycobacterium ulcerans | multifunctional mycocerosic acid synthase membrane-associated Mas | 0.0026 | 0.463 | 0.481 |
Mycobacterium tuberculosis | Phenolpthiocerol synthesis type-I polyketide synthase PpsD | 0.0025 | 0.4229 | 0.5702 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks9 | 0.0014 | 0.1448 | 0.1953 |
Onchocerca volvulus | Fatty acid synthase homolog | 0.0045 | 0.9402 | 1 |
Mycobacterium leprae | PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSB | 0.002 | 0.297 | 0.172 |
Schistosoma mansoni | hypothetical protein | 0.0012 | 0.0965 | 1 |
Toxoplasma gondii | type I fatty acid synthase, putative | 0.0018 | 0.2372 | 0.3471 |
Mycobacterium ulcerans | thioesterase TesA | 0.0021 | 0.3155 | 0.2064 |
Mycobacterium leprae | PROBABLE THIOESTERASE TESA | 0.0021 | 0.3155 | 0.2064 |
Mycobacterium ulcerans | polyketide synthase | 0.0026 | 0.463 | 0.481 |
Mycobacterium leprae | PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSD | 0.0025 | 0.4229 | 0.4065 |
Mycobacterium tuberculosis | Probable thioesterase TesA | 0.0021 | 0.3155 | 0.4254 |
Mycobacterium tuberculosis | Polyketide synthase Pks13 | 0.0037 | 0.7417 | 1 |
Onchocerca volvulus | 0.0023 | 0.3806 | 0.3783 | |
Loa Loa (eye worm) | acyl carrier protein | 0.0011 | 0.0748 | 0.0423 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0027 | 0.4875 | 0.5 |
Mycobacterium leprae | PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSA | 0.0025 | 0.4229 | 0.4065 |
Mycobacterium ulcerans | Type I modular polyketide synthase | 0.0025 | 0.4229 | 0.4065 |
Mycobacterium ulcerans | thioesterase | 0.0021 | 0.3155 | 0.2064 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0027 | 0.4875 | 0.5 |
Mycobacterium leprae | Probable polyketide synthase Pks1 | 0.0026 | 0.463 | 0.481 |
Mycobacterium tuberculosis | Phenolpthiocerol synthesis type-I polyketide synthase PpsA | 0.0025 | 0.4229 | 0.5702 |
Mycobacterium tuberculosis | Probable multifunctional mycocerosic acid synthase membrane-associated Mas | 0.0026 | 0.463 | 0.6242 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.